Cannabis company launches opioid alternative in California

9 October 2018
2019_biotech_test_vial_discovery_big

Garden Grove, USA-based cannabis firm C3 International has launched a new product, Idrasil, in the US state of California.

The firm says Idrasil is “the first standardized form of medical cannabis,” offering “all of the medicinal analgesic and therapeutic benefits” of the plant.

In the context of the ongoing opioid epidemic in the USA, the firm hopes to profit from physicians eager to provide patients with safe, non-addictive analgesics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology